Literature DB >> 12974739

Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy.

J Erdmann1, S Daehmlow, S Wischke, M Senyuva, U Werner, J Raible, N Tanis, S Dyachenko, M Hummel, R Hetzer, V Regitz-Zagrosek.   

Abstract

Defects in nine sarcomeric protein genes are known to cause hypertrophic cardiomyopathy (HCM). Mutation types and frequencies in large cohorts of consecutive and unrelated patients have not yet been determined. We, therefore, screened HCM patients for mutations in six sarcomeric genes: myosin-binding protein C3 (MYBPC3), MYH7, cardiac troponin T (TNNT2), alpha-tropomyosin (TPM1), cardiac troponin I (TNNI3), and cardiac troponin C (TNNC1). HCM was diagnosed in 108 consecutive patients by echocardiography (septum >15 mm, septal/posterior wall >1.3 mm), angiography, or based on a state after myectomy. Single-strand conformation polymorphism analysis was used for mutation screening, followed by DNA-sequencing. A total of 34 different mutations were identified in 108 patients: 18 mutations in MYBPC3 in 20 patients [intervening sequence (intron) 7 + 1G > A and Q1233X were found twice], 13 missense mutations in MYH7 in 14 patients (R807H was found twice), and one amino acid change in TPM1, TNNT2, and TNNI3, respectively. No disease-causing mutation was found in TNNC1. Cosegregation with the HCM phenotype could be demonstrated for 13 mutations (eight mutations in MYBPC3 and five mutations in MYH7). Twenty-eight of the 37 mutation carriers (76%) reported a positive family history with at least one affected first-grade relative; only eight mutations occurred sporadically (22%). MYBPC3 was the gene that most frequently caused HCM in our population. Systematic mutation screening in large samples of HCM patients leads to a genetic diagnosis in about 30% of unrelated index patients and in about 57% of patients with a positive family history.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974739     DOI: 10.1034/j.1399-0004.2003.00151.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  52 in total

1.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

2.  Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease.

Authors:  B Yu; N A Sawyer; M Caramins; Z G Yuan; R B Saunderson; R Pamphlett; D R Richmond; R W Jeremy; R J Trent
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  Coiled-coil nanomechanics and uncoiling and unfolding of the superhelix and alpha-helices of myosin.

Authors:  Douglas D Root; Vamsi K Yadavalli; Jeffrey G Forbes; Kuan Wang
Journal:  Biophys J       Date:  2006-01-26       Impact factor: 4.033

4.  Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy.

Authors:  Sinead L Murphy; Jason H Anderson; Jamie D Kapplinger; Teresa M Kruisselbrink; Bernard J Gersh; Steve R Ommen; Michael J Ackerman; J Martijn Bos
Journal:  J Cardiovasc Transl Res       Date:  2016-02-25       Impact factor: 4.132

5.  Hypertrophic cardiomyopathy: still connecting the dots between genotype and phenotype.

Authors:  Christine L Jellis; Milind Y Desai
Journal:  Cardiovasc Diagn Ther       Date:  2015-04

6.  Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations.

Authors:  Chika Kadota; Takuro Arimura; Takeharu Hayashi; Taeko K Naruse; Sachio Kawai; Akinori Kimura
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

7.  Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy.

Authors:  Qinghang Meng; Bidur Bhandary; Md Shenuarin Bhuiyan; Jeanne James; Hanna Osinska; Iñigo Valiente-Alandi; Kritton Shay-Winkler; James Gulick; Jeffery D Molkentin; Burns C Blaxall; Jeffrey Robbins
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

Review 8.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

Review 9.  Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.

Authors:  Amelia A Glazier; Andrea Thompson; Sharlene M Day
Journal:  Pflugers Arch       Date:  2018-11-20       Impact factor: 3.657

10.  Melusin gene (ITGB1BP2) nucleotide variations study in hypertensive and cardiopathic patients.

Authors:  Valeria Palumbo; Ludovica Segat; Lara Padovan; Antonio Amoroso; Bruno Trimarco; Raffaele Izzo; Giuseppe Lembo; Vera Regitz-Zagrosek; Ralph Knoll; Mara Brancaccio; Guido Tarone; Sergio Crovella
Journal:  BMC Med Genet       Date:  2009-12-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.